Type 2 diabetes patients set for major shake-up in care
This includes making newer type 2 diabetes drugs, known as SGLT-2 inhibitors, a first-line treatment option in a move that could eventually help save tens of thousands of lives.
SGLT-2 inhibitors, which include canagliflozin, dapagliflozin, empagliflozin, and ertugliflozin, are once-a-day tablets that reduce blood sugar levels by helping the kidneys remove glucose, which is passed from the body through urine.
However, analysis by Nice found these drugs are under-prescribed.
The new guidelines recommend patients who cannot tolerate metformin – the first-choice in type 2 diabetes medication – should start with an SGLT-2 inhibitor on its own.
The decision comes after evidence suggested these drugs protect the heart and kidneys as well as controlling blood sugar, Nice said.
It is estimated the change could save almost 22,000 lives once uptake reaches 90% of the population.
Nice also suggests some groups of patients would also benefit from GLP-1 receptor agonists such as liraglutide or semaglutide sooner, rather than keeping them for the later stages of treatment.
Semaglutide, sold under the brand name Ozempic, is licensed in the UK to treat type 2 diabetes, while its other brand – Wegovy – is also used by the NHS to help obese people lose weight.
Professor Jonathan Benger, deputy chief executive and chief medical officer at Nice, said: 'This guidance means more people will be offered medicines where it is right to do so to reduce their future risk of ill health.
'This represents a significant evolution in how we approach type 2 diabetes treatment.
'We're moving beyond simply managing blood sugar to taking a holistic view of a person's health, particularly their cardiovascular and kidney health.
'The evidence shows that certain medicines can provide important cardiovascular benefits, and by recommending them as part of initial treatment, we could help prevent heart attacks, strokes and other serious complications before they occur.
'This is particularly important given that cardiovascular disease is the leading cause of death in people with type 2 diabetes.'
Around 4.6 million people in the UK are living with diabetes, with nine in 10 of those having type 2.
However, it is estimated that a further 1.3 million people may have undiagnosed type 2 diabetes.
Nice analysed the records of 590,000 people and found SGLT-2 inhibitors are under-prescribed, particularly to women, older people, and black patients.
Prof Benger added: 'The evidence from our analysis is clear. There are prescribing gaps that need to be addressed.
'The guideline update published today will help to increase equitable uptake of SGLT-2 inhibitors, which we know can prevent serious health complications.'
Dr Waqaar Shah, chairman of the guideline committee, added: 'We know that SGLT-2 inhibitors are currently under-prescribed, and our health economics analysis shows that people living in the most deprived areas would particularly benefit from universal access to these treatments.
'These recommendations could help reduce health inequalities while providing better outcomes for everyone.'
Elsewhere, the draft guidance suggests different treatments for diabetes patients with certain characteristics or health conditions.
These include adults with cardiovascular disease, who should be offered a triple therapy including a GLP-1 receptor agonist.
Meanwhile, adults diagnosed with type 2 diabetes before 40 should be offered dual therapy before a GLP-1 receptor agonist is considered, while patients with chronic kidney disease should have tailored recommendations based on their kidney function.
A public consultation on the new Nice guidelines is open until October 2.
Douglas Twenefour, head of clinical at Diabetes UK, said: 'This long-awaited announcement propels type 2 diabetes treatment into the 21st century.
'Boosting access to newer treatments will be transformative for people with type 2 diabetes, while ensuring the UK keeps pace with the global momentum in treating the condition.
'The majority of people with type 2 diabetes are not currently taking the most effective medication for them, putting them at risk of devastating diabetes-related complications.
'Diabetes is a leading cause of cardiovascular disease, and tailoring treatment based on individual risk could protect thousands against heart attacks and kidney disease.
'These guidelines could go a long way to easing the burden of living with this relentless condition, as well as helping to address inequities in type 2 diabetes treatments and outcomes.'
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Daily Record
43 minutes ago
- Daily Record
NHS update for people with heart and CVD problems explained
New draft guidance from the National Institute for Health and Care Excellence will see six online platforms conditionally recommended to support adults Heart patients will be able to undertake rehabilitation online from their own homes instead of waiting for face-to-face appointments after several platforms received conditional approval for NHS use. Specialists said the programmes 'offer real potential to transform' how this type of care is delivered. Six online platforms have been conditionally recommended to support adults with cardiovascular disease (CVD) in new draft guidance from the National Institute for Health and Care Excellence (NICE). These are Activate Your Heart, D REACH-HF, Digital Heart Manual, Gro Health HeartBuddy, KiActiv and myHeart. CVD is a general term for conditions that impact the heart or blood vessels. It is estimated to impact approximately seven million people in the UK. Even still, according to NICE, uptake for cardiac rehabilitation programmes, which can reduce the risk of further heart problems and hospital admissions, is low. Each platform is now designed to offer cardiac rehabilitation online, including exercise programmes, diet advice, medication management, and psychological support. Some of the platforms also include wearable devices to monitor activity levels. Dr Anastasia Chalkidou, healthtech programme director at NICE, said: "These digital platforms offer real potential to transform how cardiac rehabilitation is offered to people to meet their individual circumstances. "We know that traditional programmes aren't reaching everyone who could benefit – particularly women, younger patients and people from ethnic minority backgrounds." Before the online platforms are offered as an option, patients must be assessed by a healthcare professional. NICE suggests that further support may be needed for older people, those with disabilities, homeless patients, or those whose first language is not English. The six platforms will be used on the NHS over the next three years to generate more evidence and data on their long-term effectiveness. Dr Chalkidou added: "The early data is promising and suggests, with safeguards in place, more people should now be given the opportunity to use these new technologies. "This three-year evidence collection period will give us the additional robust data we need to determine whether these innovations should be recommended as a permanent part of cardiac care." A consultation on the conditional recommendation is now underway and will close on September 3. NICE said seven other platforms - Beat Better, Datos Health, Get Ready, Luscii Vitals, Pumping Marvellous Cardiac Rehab Platform, R Plus Health, and Sword Move - require more research before they can be funded by the NHS.
The Sun
44 minutes ago
- The Sun
Thousands more Brits to be offered weight loss jabs for free as NHS relaxes rules – are you eligible?
HUNDREDS of thousands more Brits could be offered weight loss jabs on the NHS in the biggest shake up of diabetes care in a decade - as the health service prepares to ease rules around prescriptions. Under new proposed guidance, people with type 2 diabetes in England would be given Ozempic and new diabetes drugs sooner, rather than keeping them for later stages of treatment. 1 Draft guidance from the National Institute for Health and Care Excellence (NICE) stated that the NHS should rethink its one-size-fits-all approach of starting everyone on the same medication. Instead, it should offer patients more personalised care to prevent complications like heart failure and heart attacks. Officials estimate the changes could save almost 22,000 lives. Prof Jonathan Benger, the deputy chief executive and chief medical officer at NICE, said they would mean 'more people will be offered medicines where it is right to do so'. Under the guidance, doctors would be encouraged to prescribe GLP-1 receptor agonists such as liraglutide or semaglutide to diabetes patients who also have heart disease or obesity. Semaglutide, sold under the brand name Ozempic, is licensed in the UK to treat type 2 diabetes, while its other brand - Wegovy - is used to help obese people lose weight. Patients would be offered the drugs - which have also been shown to boost heart health - at diagnosis, rather than trying out other medications first. Around 754,000 patients with cardiovascular disease (CVD) or early-onset diabetes could benefit from the proposed changes on weight loss drug prescriptions, NICE said. The guidance says the jabs should be considered in diabetes patients who have also been diagnosed with heart disease, heart failure, or have early onset type 2, which means they were diagnosed before age 40. People with both diabetes and obesity – a body mass index (BMI) over 35 – will also be able to get the jabs if they have not had success in bringing down their blood sugar levels within the first three months of using another drug. NICE also called for making newer type 2 diabetes drugs, known as SGLT-2 inhibitors, a first-line treatment option for patients. SGLT-2 inhibitors, which include canagliflozin, dapagliflozin, empagliflozin, and ertugliflozin, are once-a-day tablets that reduce blood sugar levels by helping the kidneys remove glucose, which is passed from the body through urine. However, analysis by NICE found these drugs are under-prescribed, particularly to women, older people, and black patients. Prof Benger said: "The evidence from our analysis is clear. There are prescribing gaps that need to be addressed. "The guideline update published today will help to increase equitable uptake of SGLT-2 inhibitors, which we know can prevent serious health complications." The new guidelines recommend patients who can't tolerate metformin - the first-choice in type 2 diabetes medication - should start with an SGLT-2 inhibitor on its own. The decision comes after evidence suggested these drugs protect the heart and kidneys as well as controlling blood sugar, NICE said. Around 2.3 million people with type 2 diabetes are thought to be eligible for SGLT2's. Wegovy vs Ozempic - what's the difference? Ozempic is often used as a catch-all term for weight loss drugs, but the drug - whose active ingredient is semaglutide - is actually prescribed to treat type 2 diabetes and has the added benefit of making users lose weight. Its manufacturer Novo Nordisk later released a higher dose of semaglutide under the brand name Wegovy to treat obesity. Using Ozempic for weight loss would mean you're using it 'off label' and not for its intended purpose. Not only could that be dangerous to you, it could also mean you're depriving diabetes patients from vital medication. Wegovy and Ozempic are in a class of drugs called glucagon-like peptide-1 receptor agonists (GLP-1 RA). They work by mimicking the GLP-1 hormone produced naturally by your gut when you eat food, which signals to the brain that you're full and prevents you from overeating Prof Benger added: "This guidance means more people will be offered medicines where it is right to do so to reduce their future risk of ill health. "This represents a significant evolution in how we approach type 2 diabetes treatment. "We're moving beyond simply managing blood sugar to taking a holistic view of a person's health, particularly their cardiovascular and kidney health. "The evidence shows that certain medicines can provide important cardiovascular benefits, and by recommending them as part of initial treatment, we could help prevent heart attacks, strokes and other serious complications before they occur. "This is particularly important given that cardiovascular disease is the leading cause of death in people with type 2 diabetes." Around 4.6 million people in the UK are living with diabetes, with nine in 10 of those having type 2. However, it is estimated that a further 1.3 million people may have undiagnosed type 2 diabetes. The proposed changes won't be instituted just yet, as a public consultation on the NICE guidelines is open until October 2. Douglas Twenefour, head of clinical at Diabetes UK, said: "This long-awaited announcement propels type 2 diabetes treatment into the 21st century. "Boosting access to newer treatments will be transformative for people with type 2 diabetes, while ensuring the UK keeps pace with the global momentum in treating the condition. The 7 fat jab mistakes stopping you losing weight WHILE weight loss jabs have been hailed as a breakthrough in helping tackle Britain's obesity crisis, some users say they're missing out on their waist-shrinking powers - and it could be down to some simple mistakes... POOR PENMANSHIP Many people don't correctly use the injection pen, according to Ana Carolina Goncalves, a pharmacist at Pharmica in Holborn, London. Make sure to prime your weight loss pen correctly, as per the instructions. If nothing comes out, try again, and if it still doesn't work, switch the needle or ask a pharmacist for help. It's also recommended to rotate injection sites between the abdomen, thigh and upper arm to avoid small lumps of fat under the skin. TIME IS OF THE ESSENCE Make sure you're using the jabs on the most effective day of your schedule. For example, taking the jab right before a takeaway or party won't stop you from indulging, says Jason Murphy, head of pharmacy and weight loss expert at Chemist4U. Weight loss injections need time to build up in your system, so if you're planning for a heavier weekend, inject your dose mid-week. MAKING A MEAL OF IT You may not feel the urge to overeat at mealtimes due to the jabs. But skipping meals altogether can backfire, says Dr David Huang, director of clinical innovation at weight loss service Voy. If a person is extremely malnourished, their body goes into emergency conservation mode, where their metabolism slows down. FOOD FOR THOUGHT A key mistake using weight loss jabs is not eating the right foods. As well as cutting out sugary drinks and alcohol, Dr Vishal Aggarwal, Healthium Clinics recommends focusing on your protein intake. DE-HYDRATION STATIONS Dehydration is a common side effect of weight loss injections. But it's important to say hydrated in order for your body to function properly. Dr Crystal Wyllie, GP at Asda Online Doctor, says hydration supports metabolism, digestion, and can reduce side effects like headaches, nausea and constipation. MOVE IT, MOVE IT It can be easy to see the jabs as a quick fix, but stopping exercising altogether is a mistake, says Mital Thakrar, a pharmacist from Well Pharmacy. Exercise helps maintain muscle mass and help shape the body as you lose weight, which may be crucial if you're experiencing excess skin. QUIT IT While there's the tendency to ditch the jabs as soon as you reach your desired weight, stopping them too soon can cause rapid regain. Mr Thakrar recommends building habits like healthier eating during treatment for sustaining results. "The majority of people with type 2 diabetes are not currently taking the most effective medication for them, putting them at risk of devastating diabetes-related complications. "Diabetes is a leading cause of cardiovascular disease, and tailoring treatment based on individual risk could protect thousands against heart attacks and kidney disease. "These guidelines could go a long way to easing the burden of living with this relentless condition, as well as helping to address inequities in type 2 diabetes treatments and outcomes." Earlier this month, drug maker Eli Lilly would hike up the price of its weight loss jab Mounjaro from September 1, meaning the price of the drug in UK private clinics will almost double. Patients have been scrambling to get their hands.
Glasgow Times
an hour ago
- Glasgow Times
Mounjaro prices hike sees patients switch to cheaper Wegovy
Google Trends shows a +5,500% increase for 'can I swap from Mounjaro to Wegovy' since last Thursday, highlighting that people in the UK and Northern Ireland are searching for a more cost-effective treatment to continue their weight loss journey. There has also been issues with some pharmacies running out of stock of Moumjaro, as patients try to get supplies before the price hike. Mounjaro users report surprising side effect - pharmacists share their tips — Bucks Free Press (@bucksfreepress) August 8, 2025 'With Mounjaro's price rise looming, it's not surprising that patients are exploring alternatives," says Jason Murphy, Head of Pharmacy at Chemist4U. "Wegovy offers a safe, less expensive and almost equally effective weight loss solution and is a very good option to consider if Mounjaro becomes unaffordable. 'However, switching should always be as part of a conversation with your pharmacist or GP. Our role is to guide patients through the process, tailoring advice to their health history, so they can continue their weight loss journey with confidence.' Both medications are part of a group called GLP-1 receptor agonists What is Wegovy? Is it the same as Ozempic? Wegovy and Mounjaro are both weekly injections originally designed for type 2 diabetes but are powerful weight-loss drugs. Wegovy (the brand name for semaglutide) works by mimicking a gut hormone (GLP-1) that curbs appetite and slows digestion. Semaglutide is also branded as Ozempic for managing type 2 diabetes, but is not prescribed for weight-loss in the UK. Mounjaro goes a step further by also targeting a second hormone, GIP. 'When moving from Mounjaro to Wegovy, it's not a one-size-fits-all process," says Jason. "Your starting Wegovy dose should always reflect the Mounjaro dose you were previously on, alongside your overall health, and how well you tolerated treatment. That's why a pharmacist's review is essential; it ensures the transition is safe, effective, and tailored to your individual needs.' Who is eligible for Wegovy? For those who have not taken a weight loss injection before, Wegovy has the same eligibility criteria as Mounjaro. This means a BMI of 30 or higher, or a BMI of 27 or higher with a pre-existing medical condition that is affected by weight (e.g., cardiovascular disease or high blood pressure). This might be more complicated for patients who have already lost weight on Mounjaro and are now below a BMI of 30, or 27, and now looking to continue their weight-loss, but experts recommend speaking a doctor or pharmacist. How do you switch from Mounjaro to Wegovy? Jason says that when switching, it's important to not stop Mounjaro until your prescriber confirms the switch to Wegovy is possible. But, he cautions: 'Please note that the manufacturer recommends leaving 30 days from your last dose of Mounjaro and your first dose of Wegovy, to further reduce the risk of side effects, however we understand this could result in stalling your weight loss journey or potential weight gain.' He adds that if you've already lost weight while taking Mounjaro, or are using it to maintain your weight, and are now below the eligibility criteria, you may still be able to switch to Wegovy; a clinical team will review your medical history and decide if it's safe and suitable. Recommended reading: What are the Wegovy and Mounjaro side effects? People respond to medications in different ways, and even though Mounjaro and Wegovy share similar ingredients, some people may tolerate one better than another. Jason adds: 'There are no 'withdrawal' symptoms in the usual sense. Some people notice their appetite increases as the medicine wears off, and any side effects usually settle after stopping. If you feel unwell or are unsure what to expect, speak to your prescriber. 'It's unlikely you'll gain weight when switching, as the effects of Mounjaro will continue during the seven days after your final dose. You will then immediately start taking Wegovy, which will continue to work in the same way. This means you can continue losing weight while switching, especially if you're sticking to your diet and exercise plan.'
